ArticleOrphanet journal of rare diseases2018

Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA).

Alberto Jiménez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.